VANDA PHARMACEUTICALS INC.
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $165.1M | $146.0M | $109.9M | $50.2M | $33.9M | $32.7M | $31.3M | $35.7M |
| Cost of Revenue | — | — | $23.5M | $1.6M | — | $129.0K | — | $2.9M |
| Gross Profit | — | — | $86.5M | $48.6M | — | $32.6M | — | $32.8M |
| Gross Margin | — | — | 78.7% | 96.8% | — | 99.6% | — | 91.9% |
| Operating Expenses | ||||||||
| Research & Development | $38.5M | $29.2M | $29.1M | $19.2M | $28.5M | $45.8M | $29.0M | $12.3M |
| SG&A Expense | $123.8M | $99.8M | $84.5M | $84.6M | $25.1M | $14.5M | $11.5M | $10.1M |
| Operating Income | $-16.9M | $-18.6M | $-40.2M | $20.1M | $-21.2M | $-29.2M | $-10.7M | $8.8M |
| Operating Margin | -10.2% | -12.7% | -36.6% | 40.0% | -62.6% | -89.2% | -34.2% | 24.8% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-15.4M | $-17.9M | $-39.9M | $20.2M | $-20.3M | $-27.7M | $-10.2M | $9.3M |
| Income Tax Expense | $136.0K | $104.0K | $0 | $0 | $0 | — | $-444.0K | $2.1M |
| Net Income | $-15.6M | $-18.0M | $-39.9M | $20.2M | $-21.1M | $-28.6M | $-9.8M | $7.2M |
| Net Margin | -9.4% | -12.3% | -36.3% | 40.2% | -62.1% | -87.4% | -31.3% | 20.1% |
| EPS (Basic) | $-0.35 | $-0.41 | $-0.94 | $0.58 | $-0.69 | $-1.01 | $-0.35 | $0.26 |
| EPS (Diluted) | $-0.35 | $-0.41 | $-0.94 | $0.55 | $-0.69 | $-1.01 | $-0.35 | $0.25 |
| Shares Outstanding (Basic) | 44.7M | 43.4M | 42.3M | 34.8M | 30.4M | 28.2M | 28.1M | 27.9M |
| Shares Outstanding (Diluted) | 44.7M | 43.4M | 42.3M | 36.7M | 30.4M | 28.2M | 28.1M | 28.5M |
| Dividends Per Share | — | — | — | — | — | — | — | — |